Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

154.49
+1.971.29%
Post-market: 154.490.00000.00%19:30 EDT
Volume:179.30K
Turnover:27.62M
Market Cap:6.22B
PE:-56.42
High:155.99
Open:152.73
Low:152.17
Close:152.52
52wk High:200.00
52wk Low:77.64
Shares:40.27M
Float Shares:19.55M
Volume Ratio:1.18
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:8.01
PE(LYR):-66.76

Loading ...

Belite Bio CSO Nathan L. Mata disposes 666 shares worth $102,274.53

Reuters
·
May 09

Belite Bio CSO Nathan L. Mata reports disposal of shares worth $153,957.36

Reuters
·
May 08

Belite Bio CSO Nathan L. Mata sells shares worth $155,707.57

Reuters
·
May 06

Belite Bio CSO Nathan L. Mata disposes of shares worth $156,299.79

Reuters
·
May 05

Belite Bio CSO Nathan L. Mata disposes of $157,037 in common shares

Reuters
·
May 02

Belite Bio CSO Nathan L. Mata disposes of ADSs worth $157,936.14

Reuters
·
Apr 30

Belite Bio CSO Nathan L. Mata disposes of USD 158,424 in shares

Reuters
·
Apr 28

Belite Bio to present Phase 3 tinlarebant Stargardt data at Retinal Therapeutics summit

Reuters
·
Apr 27

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

GlobeNewswire
·
Apr 27

Belite Bio CSO Nathan L. Mata disposes of shares worth $165,863

Reuters
·
Apr 25

Belite Bio to Participate in Four Upcoming Investor Conferences

GlobeNewswire
·
Apr 23

Belite Bio CMO to present at Deutsche Bank ADR virtual investor conference

Reuters
·
Apr 22

Belite Bio Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 22

Belite Bio CSO Nathan L. Mata disposes of shares worth $163,995.76

Reuters
·
Apr 22

Belite Bio Starts Rolling Submission of New Drug Application for Eye Treatment

Dow Jones
·
Apr 22

Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant

TIPRANKS
·
Apr 22

Belite Bio starts FDA rolling NDA submission for tinlarebant in Stargardt disease

Reuters
·
Apr 22

Belite Bio Inc - Expects to Complete Nda Rolling Submission in Q2 2026

THOMSON REUTERS
·
Apr 22

Belite Bio Inc - Tinlarebant Granted Breakthrough Therapy Designation by FDA for Stargardt Disease

THOMSON REUTERS
·
Apr 22

Belite Bio CSO Nathan L. Mata disposes of shares worth $159,910

Reuters
·
Apr 21